Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Core Viewpoint - Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, with a corporate update presentation scheduled at the Piper Sandler 36th Annual Healthcare Conference [1]. Company Overview - Nurix Therapeutics specializes in the discovery, development, and commercialization of innovative small molecules and antibody therapies that modulate cellular protein levels [3]. - The company utilizes an integrated discovery platform called DELigase, which focuses on identifying and advancing drug candidates targeting E3 ligases, a class of enzymes that modulate proteins within cells [3]. - Nurix's clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, which are involved in immune cell regulation [3]. - The company is headquartered in San Francisco, California [3].